Anterior Uveitis Global Market Report 2025

Anterior uveitis is an inflammatory condition affecting the eye's middle layer, including the iris and ciliary body. It can result from eye trauma, such as a direct injury or a foreign object, or be associated with systemic conditions such as rheumatoid arthritis, syphilis, tuberculosis, sarcoidosis, or viral infections (herpes simplex, herpes zoster, cytomegalovirus). In some cases, the cause remains idiopathic, with no identifiable underlying factor.

The primary treatment options for anterior uveitis include pharmacological therapies, surgical interventions, and biologic treatments. Pharmacological therapies involve medications to reduce inflammation and manage symptoms. Diagnosis is conducted through clinical evaluation, diagnostic imaging, and biomarker testing. The condition may have infectious or non-infectious origins and is managed in hospitals, clinics, and ambulatory surgical centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The anterior uveitis market research report is one of a series of new reports from The Business Research Company that provides anterior uveitis market statistics, including the anterior uveitis industry's global market size, regional shares, competitors with a anterior uveitis market share, detailed anterior uveitis market segments, market trends and opportunities, and any further data you may need to thrive in the anterior uveitis industry. This anterior uveitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anterior uveitis market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.57 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increase in prevalence of autoimmune disorders, rise in awareness of eye health, improved access to healthcare, growth in use of corticosteroids and biologics, expanding research on immunological pathways, and rise in aging population.

The anterior uveitis market size is expected to see rapid growth in the next few years. It will grow to $0.88 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to growing awareness of autoimmune diseases, increasing adoption of biologic therapies, rising prevalence of inflammatory conditions, rising healthcare expenditure, and ongoing research into personalized medicine. Major trends in the forecast period include advancements in novel biologics, adoption of corticosteroid delivery systems, advanced diagnostic imaging, personalized medicine approaches, targeted immunomodulators, adoption of minimally invasive surgical techniques, and innovation in digital health tools.

The forecast of 11.4% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. ophthalmology by driving up the cost of corticosteroid eye implants and immunosuppressive drops sourced from Israel and Belgium, exacerbating treatment costs for ocular inflammation and limiting medication access. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of autoimmune diseases is expected to drive growth in the anterior uveitis market. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells and tissues, perceiving them as foreign threats. This abnormal response leads to inflammation and damage in various organs and systems. The rise in autoimmune diseases is attributed to genetic predisposition, environmental factors, lifestyle changes, and improved awareness leading to better diagnosis. Anterior uveitis is a common inflammatory eye condition associated with autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. As a result, the growing incidence of autoimmune diseases is fueling the expansion of the anterior uveitis market.

Leading companies in the anterior uveitis market are advancing treatment approaches by developing innovative drug formulations such as eye drops to improve patient compliance, enhance drug delivery, and reduce inflammation with fewer side effects. Eye drops are widely used to manage anterior uveitis by controlling inflammation, alleviating pain, and preventing complications. For instance, in January 2024, Tarsier Pharma Ltd., an Israel-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the clinical trial protocol and statistical analysis plan of the Tarsier-04 Phase 3 trial. This trial aims to assess the effectiveness of TRS01 eye drops in treating non-infectious uveitis, including uveitic glaucoma. The Tarsier-04 trial is a multicenter, randomized, double-masked, active-controlled study enrolling up to 300 patients in the U.S., with the objective of demonstrating TRS01's safety and efficacy, particularly in controlling inflammation without increasing the risk of glaucoma.

In January 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Oxular Limited for an undisclosed amount. This acquisition enhances Regeneron's capabilities in ocular gene therapies by integrating an advanced delivery device, expediting the development of clinical treatments. By leveraging Oxular's proprietary technologies, Regeneron aims to improve therapeutic precision and drive innovation in eye care. Oxular Limited is a UK-based biotech company specializing in drug and device treatments for retinal disorders, including anterior uveitis.

Major players in the anterior uveitis market are AbbVie Inc., Novartis AG, Amgen Inc., Aerie Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Bausch & Lomb Incorporated, Cipla Ltd., Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals Ltd., Santen Pharmaceutical Co. Ltd., HanAll Biopharma Co. Ltd., EyePoint Pharmaceuticals Inc., Kiora Pharmaceuticals Inc., Clearside Biomedical Inc., Oculis SA, Aldeyra Therapeutics Inc., Lux Biosciences Inc., Tarsier Pharma Ltd., Xoma Corporation.

North America was the largest region in the anterior uveitis market in 2024. The regions covered in anterior uveitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anterior uveitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anterior uveitis market consists of revenues earned by entities by provide services such as slit-lamp examinations, optical coherence tomography (OCT), ultrasound biomicroscopy, corticosteroid administration, and glaucoma management. The market value includes the value of related goods sold by the service provider or included within the service offering. The anterior uveitis market also includes sales of corticosteroids (topical and systemic), non-steroidal anti-inflammatory drugs (NSAIDS), and immunosuppressive drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anterior Uveitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anterior uveitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anterior uveitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anterior uveitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Pharmacological Treatments; Surgical Treatments; Biologic Therapy
• 2) By Diagnosis Method: Clinical Diagnosis; Diagnostic Imaging; Biomarkers
• 3) By Cause: Infectious; Non-Infectious
• 4) By End-User: Hospitals And Clinics; Ambulatory Surgical Centers
• Subsegments:
• 1) By Pharmacological Treatments: Corticosteroids; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Immunosuppressive Drugs
• 2) By Surgical Treatments: Cataract Surgery; Glaucoma Surgery; Vitrectomy
• 3) By Biologic Therapy: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; Monoclonal Antibodies
• Companies Mentioned: AbbVie Inc.; Novartis AG; Amgen Inc.; Aerie Pharmaceuticals Inc.; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; UCB S.A.; Bausch & Lomb Incorporated; Cipla Ltd.; Hikma Pharmaceuticals PLC; Cadila Pharmaceuticals Ltd.; Santen Pharmaceutical Co. Ltd.; HanAll Biopharma Co. Ltd.; EyePoint Pharmaceuticals Inc.; Kiora Pharmaceuticals Inc.; Clearside Biomedical Inc.; Oculis SA; Aldeyra Therapeutics Inc.; Lux Biosciences Inc.; Tarsier Pharma Ltd.; Xoma Corporation.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.